Drug Groups

withdrawn

Description

Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

Indication

For the treatment of depression (originally intended to treat tuberculosis).

Pharmacology

Iproniazid is a monoamine oxidase inhibitor (MAOI) that was developed as the first anti-depressant.

Affected Organisms

External Links